Avandia Articles
Future growth of the global pharmaceutical market evaluated by MSDW
23 February 1999
Troglitazone; great potential despite woes
18 February 1999
Takeda entering new phase of global expansion, says MSDW analyst
18 February 1999
Stock Commentary Europe
4 February 1999
Stock Commentary Tokyo
28 January 1999
SB's Avandia gets priority US review
27 January 1999
SB's Avandia gets priority US review
22 January 1999
Stock Commentary Europe
20 January 1999
Rezulin up for FDA panel review on safety, plus new indications
19 January 1999
AstraZeneca's Effect On Rest Of Pharma Sector
17 December 1998
Stock Commentary Tokyo
10 December 1998
SB To Jointly Commercialize Coulter's Cancer Therapy
8 December 1998
SB Submits Avandia NDA To FDA
3 December 1998
Pioglitazone; Competition For Rezulin/Avandia?
26 November 1998
Stock Commentary Tokyo
5 November 1998
Stock Commentary Europe
29 October 1998
Solid Third Quarter At SB Thanks To New Products
20 October 1998
Stock Commentary Europe
30 September 1998
Stock Commentary Europe
24 September 1998
SmithKline Beecham's Avandia Shines At Phase III
17 September 1998
Currency And Flu Factors Hold Back SB Results
22 July 1998
Stock Commentary Europe
16 July 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Rosiglitazone Success In Phase III Boosts SB
18 June 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
SmithKline Shares Drop On R&D Presentation
16 April 1998
Neutral Rating For GW And SB From MSDW
10 March 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Stock Commentary Europe
4 December 1997
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
